Key Takeaways HRMY shares dropped 16.56% after ZYN002 missed its main goal in the RECONNECT Fragile X study.Wakix generated $200.5M in Q2, with new phase III trials set to begin in narcolepsy and hypersomnia.HRMY expanded into rare epilepsy via Epygenix buyout, adding EPX-100 and EPX-200 to its pipeline.Shares of Harmony Biosciences Holdings, Inc. (HRMY) lost 16.56% on Sept. 24 after the company announced the failure of the late-stage registrational RECONNECT study on pipeline candidate ZYN002 in Fragile X ...